Clinical Trials

144 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT05063565 2026-03-02

ROWAN

100 enrolled

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT05014776 2026-02-24

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

17 enrolled 8 charts

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT03504397 2026-02-13

Spotlight

565 enrolled 63 charts 1 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03653507 2026-02-06

GLOW

507 enrolled 65 charts 1 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

80 enrolled

Adenocarcinoma

NCT06564844 2026-01-27

TROPION-Lung12

Phase 2/3 Active not recruiting

24 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

580 enrolled

Adenocarcinoma

NCT04704934 2026-01-12

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

490 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT05273554 2026-01-12

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

15 enrolled

Adenocarcinoma, Neoplasms

NCT07302451 2026-01-06

REDI-CaP

50 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT02864992 2025-12-23

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

337 enrolled 13 charts 2 FDA

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00756639 2025-12-17

Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

31 enrolled

CNSGenitourinary

Adenocarcinoma, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell

NCT01512589 2025-10-10

Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial

147 enrolled

Phase 1/2 Active not recruiting

Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT05585320 2025-09-02

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

209 enrolled

DermatologicThoracic

Melanoma, Cutaneous Malignant, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01088789 2025-08-26

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

71 enrolled 13 charts

Adenocarcinoma, Pancreatic Neoplasms

NCT05226507 2025-08-08

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

45 enrolled

Gynecologic

Adenocarcinoma, Carcinoma, Neoplasms, Ovarian Neoplasms

NCT01952223 2025-07-30

PEACE2

761 enrolled

Adenocarcinoma, Recurrence

NCT05604560 2025-07-23

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

25 enrolled

Adenocarcinoma, Pancreatic Neoplasms

NCT04879368 2025-07-17

INTEGRATEIIb

450 enrolled

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT04864067 2025-07-01

NOAHS-ARC

73 enrolled

Adenocarcinoma, Rectal Neoplasms

NCT00911118 2025-06-03

Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

120 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

423 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT04627246 2025-02-25

Personalized Vaccine with SOC Chemo Followed by Nivo in Pancreatic Cancer

14 enrolled

Adenocarcinoma, Neoplasms

NCT04660929 2024-12-18

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

48 enrolled

Carcinoma, Ovarian Epithelial, Adenocarcinoma, Bile Duct Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Small Cell, Carcinoma, Ductal, Small Cell Lung Carcinoma, Inflammatory Breast Neoplasms

NCT05128487 2024-11-25

A Study of NDI 1150-101 in Patients With Solid Tumors

Phase 1/2 Active not recruiting

106 enrolled

GenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT01171300 2024-07-10

Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients

Phase NA Active not recruiting

94 enrolled

Adenocarcinoma, Rectal Neoplasms

NCT02509286 2024-05-08

ESOPEC

438 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

NCT04544748 2024-03-06

A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies

DermatologicGenitourinaryThoracic

48 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Neoplasms by Histologic Type, Urologic Neoplasms

NCT03132922 2024-01-22

MAGE-A4ᶜ¹º³²T for Multi-Tumor

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

71 enrolled

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT03488667 2023-05-19

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

40 enrolled